Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
2011
Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
4
Citations
NaN
KQI